Shanghai Fosun Pharmaceutical Group Co Ltd

Fosun Pharma’s new guarantee amid China’s 2026 drug‑benefit reforms may boost pipeline funding, yet raises liquidity risks – a nuanced view for investors and execs.

Explore Fosun Pharma’s 2025 AGM: hybrid voting, share buybacks, audit changes & market dynamics that shape shareholder value and R&D strategy.

Fosun Pharma secures EU drug‑indication approval and U.S. trial launch, boosting EU reach to 450 million and positioning for $120 M revenue while driving cost‑efficient growth and value‑based pricing.

Fosun Pharmaceutical’s new drug approval promises $350‑450M sales in 3 years, boosting market access, securing 10‑year exclusivity, and opening M&A and partnership opportunities.

Shanghai Fosun Pharma’s latest drug approval boosts 2025 revenue, cuts R&D costs, and positions the company for value‑based pricing and digital supply‑chain gains.

Fosun Pharma partners with Arcera Life Sciences to accelerate neurodegenerative, oncology, and rare disease therapies—boosting global access to next‑gen drugs, including Alzheimer’s breakthroughs.

Shanghai Fosun Pharma’s 2025 turnaround: 12.4 % revenue growth, net profit up to ¥0.3 bn, and a robust biosimilar & GLP‑1 pipeline poised for global expansion.

Explore why Shanghai Fosun Pharmaceutical’s quiet market stance matters, the hidden pipeline insights, and how investors and partners can spot its next breakthrough in China’s innovation‑drug scene.

Shanghai Fosun Pharmaceutical Q4 2025 outlook: stable EPS, slight revenue dip, and a robust pipeline featuring a KRAS G12C oncology lead and a GLP‑1 diabetes candidate, all under strong cost‑control strategy.

Shanghai Fosun Pharma’s Q4 2025 outlook: steady EPS, a modest revenue lift, and a shift to high‑margin oncology drugs. Discover how the company plans to navigate pricing, patent cliffs, and M&A opportunities in China’s specialty‑drug market.